Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06FOU
|
|||
| Former ID |
DIB008018
|
|||
| Drug Name |
Trifarotene
|
|||
| Synonyms |
Trifarotene; UNII-0J8RN2W0HK; 895542-09-3; CD5789; 0J8RN2W0HK; Trifarotene [USAN:INN]; CD 5789; SCHEMBL381493; GTPL9962; CHEMBL3707313; DTXSID30237781; EX-A2704; DB12808; compound 15b [PMID: 29706423]; 3''-Tert-butyl-4'-(2-hydroxyethoxy)-4''-(pyrrolidin-1-yl)(1,1':3',1'')terphenyl-4-carboxylic acid; HY-100256; CS-0018407; 4-[3-(3-tert-butyl-4-pyrrolidin-1-ylphenyl)-4-(2-hydroxyethoxy)phenyl]benzoic acid; [1,1':3',1''-Terphenyl]-4-carboxylic acid, 3''-(1,1-dimethylethyl)-4'-(2-hydroxyethoxy)-4''-(1-pyrrolidinyl)-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Acne vulgaris [ICD-11: ED80; ICD-10: L70.0; ICD-9: 706.1] | Approved | [1] | |
| Company |
Galderma
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C29H33NO4
|
|||
| Canonical SMILES |
CC(C)(C)C1=C(C=CC(=C1)C2=C(C=CC(=C2)C3=CC=C(C=C3)C(=O)O)OCCO)N4CCCC4
|
|||
| InChI |
1S/C29H33NO4/c1-29(2,3)25-19-23(10-12-26(25)30-14-4-5-15-30)24-18-22(11-13-27(24)34-17-16-31)20-6-8-21(9-7-20)28(32)33/h6-13,18-19,31H,4-5,14-17H2,1-3H3,(H,32,33)
|
|||
| InChIKey |
MFBCDACCJCDGBA-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 895542-09-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Retinoic acid receptor gamma (RARG) | Target Info | Agonist | [1] |
| Reactome | Nuclear Receptor transcription pathway | |||
| WikiPathways | Vitamin A and Carotenoid Metabolism | |||
| Nuclear Receptors in Lipid Metabolism and Toxicity | ||||
| Mesodermal Commitment Pathway | ||||
| Endoderm Differentiation | ||||
| Nuclear Receptors | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.